Stay updated on Propranolol and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Propranolol and Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed information about a clinical trial for propranolol and pembrolizumab in treating melanoma, while adding a new registry identifier and a revision update.SummaryDifference43%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 27, 2025, while a previous date of March 25, 2025, has been removed.SummaryDifference0.4%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe webpage has updated its date references, adding new future dates while removing older ones. The last update notice has also been modified to reflect an estimated posting.SummaryDifference2%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Propranolol and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.